Efferon wants to wipe out paediatric sepsis with blood cleansing

Efferon is developing blood-cleansing therapies designed to stop paediatric sepsis, the runaway immune reaction to infection that remains one of the leading causes of death in children worldwide. The company's pitch is that antibiotics alone cannot save a child once their own immune system turns on them, so the treatment has to target the body's response rather than just the pathogen.

What paediatric sepsis actually is

Sepsis is often misdescribed as "blood poisoning". It is not the infection itself but the body's extreme reaction to it. When a child's immune system detects an infection, it floods the bloodstream with signalling molecules called cytokines. These are meant to coordinate the defence, calling immune cells to the site of the problem.

In sepsis, that system loses control. The cytokine release becomes widespread and indiscriminate, causing inflammation across the entire body. Blood vessels leak, blood pressure collapses, and organs including the kidneys, lungs and liver begin to fail. This state is sometimes called a cytokine storm, and it is the storm, not the bacteria, that typically kills.

In children the picture is especially cruel. Paediatric sepsis can develop within hours from what looks like a routine fever, and early symptoms overlap heavily with far more common and benign childhood illnesses. By the time the diagnosis is clear, the immune cascade is already well underway.

How blood purification is meant to work

Efferon's core idea belongs to a category called extracorporeal blood purification. Extracorporeal simply means "outside the body". Blood is drawn from the patient, passed through a device that filters or adsorbs specific molecules, and returned.

The analogy that clinicians tend to reach for is dialysis. In kidney failure, a machine removes waste products the kidneys can no longer clear. In sepsis, the target is different: the aim is to pull out the excess cytokines and bacterial toxins circulating in the blood, lowering their concentration and, in theory, dialling down the inflammatory signal before it causes permanent organ damage.

There are a few ways to do this. One is haemoadsorption, where blood passes over a cartridge containing a material that binds and traps the offending molecules. Another uses specialised membranes that selectively filter by molecular size. Some systems combine both.

The concept is not new. Similar devices have been used in adults for years, particularly in severe sepsis and in the cytokine storms seen after certain cancer treatments. What Efferon appears to be pursuing is the paediatric applications specifically, where the technical demands are different: smaller blood volumes, different flow rates, and a body that is still developing.

Who uses this and why children are the hard part

Sepsis devices are typically deployed in intensive care units, by critical care teams, on patients who are already deteriorating despite antibiotics and fluid resuscitation. The named players in this space include companies like CytoSorbents, whose cytokine adsorption cartridge is widely used in adult critical care across Europe, and Baxter and Fresenius, which dominate the broader blood filtration market through their dialysis and CRRT (continuous renal replacement therapy) machines. Efferon is positioning itself among these, but with a paediatric focus.

That focus matters, and it is also the reason progress has been slow. Children are routinely excluded from critical care trials because their physiology differs so much from adults, and because the ethical bar for testing an invasive therapy on a sick child is very high. Consent is difficult to obtain in an emergency. Blood volume is small, so any extracorporeal circuit has to be miniaturised and carefully primed. A device that works beautifully on a 80kg adult may be dangerous on a 12kg child.

This is the gap Efferon is targeting. If paediatric sepsis is neglected because it is hard to study, then a company willing to do the hard study has a genuine claim on the market.

What the limitations are

Honesty is warranted here, because extracorporeal blood purification has a mixed record. Multiple trials of cytokine-removing devices in adult sepsis have failed to show a clear mortality benefit. The reasons are debated. The intervention may simply arrive too late, after organ damage is irreversible. Removing cytokines indiscriminately may also remove useful ones, blunting the immune response when the patient still needs it to fight the underlying infection. And the underlying infection still has to be treated; blood purification is adjunctive, not curative.

For children, the unknowns are larger. The correct dose, timing and patient selection are all unresolved. Small trials in paediatric sepsis have shown changes in inflammatory markers, but demonstrating that those changes translate into more children walking out of hospital alive requires large, expensive, multi-centre studies that take years.

Cost is another factor. These cartridges and circuits are not cheap, and reimbursement for sepsis devices varies enormously between health systems. In the UK, NICE has been cautious about adopting blood purification for sepsis outside research settings. Any company arguing for paediatric use will face the same scrutiny, with the added burden of proving benefit in a smaller patient population.

Key takeaways

The headline claims around any sepsis breakthrough deserve scepticism. Sepsis mortality has fallen over recent decades, but that is largely due to faster recognition, better antibiotics and improved intensive care, not to any single device. Blood purification remains a promising but unproven adjunct.

That said, the underlying science is sound. Cytokine removal does lower circulating inflammatory mediators. The open question is whether that translates into survival, and in which patients. Efferon's wager is that children, whose immune systems behave differently and whose sepsis is often driven by particularly aggressive inflammatory responses, may be the population where the benefit is clearest.

What this means in practice

For clinicians, the practical takeaway is that paediatric sepsis care still rests on the fundamentals: early recognition, rapid antibiotics, fluids and organ support. Blood purification is not a replacement for any of those. If Efferon's therapy reaches clinical use, it will most likely sit alongside them in the ICU, for the sickest children who are not responding.

For parents, the more useful message is about recognition. Sepsis in a child can look like a bad flu: fever, lethargy, fast breathing, mottled skin, confusion. These are reasons to seek urgent care, not to wait. The best current intervention remains speed.

For investors and industry watchers, the question is whether Efferon can do what larger device makers have not: run the trials that generate unambiguous paediatric evidence. That is expensive and slow, and it requires partnership with children's hospitals rather than a pure commercial rollout.

Where this is heading

The broader direction of sepsis research is shifting from attacking the pathogen to managing the host. The same logic that drives blood purification also drives interest in immunomodulatory drugs, biomarkers that identify which patients will benefit from which intervention, and precision approaches that match therapy to the specific inflammatory profile of a patient. The two tribes visible at Disrupt 2026, one chasing efficiency and the other moonshots, map neatly onto this divide: incremental ICU improvements versus fundamentally rethinking how the immune response is controlled.

There is also a data and trust dimension. As device makers collect more physiological data from critically ill children, questions about security and governance arrive quickly. The warnings from Microsoft's Satya Nadella that every AI model should be treated as compromised from day one apply with particular force to connected medical hardware. And the grim ransomware economics illustrated by the collapse of a ransomware recovery firm that allegedly paid the criminals itself show how vulnerable hospital infrastructure remains, which is exactly where these devices would live.

Efferon's ambition is legitimate and the unmet need is real. The test will be whether the company can produce the kind of rigorous paediatric evidence that has so far eluded the adult sepsis device market. If it can, it will have built something more valuable than a product: a template for studying critical care in children, a group medicine has spent decades treating as an afterthought.